(Q30996799)

28 June 2017

Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy (English)

1 reference

28 June 2017

0 references

0 references

0 references

0 references

Tapan K Khan

1

1 reference

PubMed ID

26402622

28 June 2017

Daniel L Alkon

series ordinal

2

1 reference

28 June 2017

1 June 2015

1 reference

Journal of Alzheimer's Disease

28 June 2017

1 reference

28 June 2017

46

1 reference

28 June 2017

4

1 reference

28 June 2017

817-836

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

28 June 2017

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

A novel pathway for amyloid precursor protein processing

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Presenilin: running with scissors in the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Neurotoxicity of amyloid β-protein: synaptic and network dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Fluid biomarkers in Alzheimer's disease - current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid markers for prediction of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

CSF biomarker levels in early and late onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Subcortical vascular dementia biomarker pattern in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Post-lumbar puncture syndrome and spontaneous low CSF pressure syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Post-lumbar puncture headaches: experience in 501 consecutive procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Safety of lumbar puncture procedures in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

International quality control survey of neurochemical dementia diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

What is a certified reference material?

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Analytical aspects of molecular Alzheimer's disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Spectrophotometry for cerebrospinal fluid pigment analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed Alzheimer's disease peripheral biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Structural MRI biomarkers for preclinical and mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

The clinical use of structural MRI in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Role of structural MRI in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta-analyses of MRI studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Medial temporal lobe atrophy on MRI in dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Frontotemporal dementia and Alzheimer's disease: differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Structural imaging markers for therapeutic trials in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Neuroimaging outcomes in clinical trials in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Topography of brain atrophy during normal aging and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Progression of corpus callosum atrophy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Volumetric reduction of the corpus callosum in Alzheimer's disease in vivo as assessed with voxel-based morphometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

White matter atrophy in Alzheimer's disease variants

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Evidence of altered posteromedial cortical FMRI activity in subjects at risk for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Early detection of Alzheimer disease: ¹¹C-PiB PET in twins discordant for cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-alzheimer disease-type dementia as having AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

PET of brain amyloid and tau in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Relationships between biomarkers in aging and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

CSF biomarkers for Alzheimer's disease: current utility and potential future use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Biomarkers in Alzheimer's disease: not yet surrogate endpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

An MRI-based index to measure the severity of Alzheimer's disease-like structural pattern in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150238

21 January 2018

Identifiers

DOI

10.3233/JAD-150238

1 reference

28 June 2017

1 reference

PubMed ID

26402622